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The patch described in this paper combines the principles of wet adhesion, which is a widely adopted
biological adhesion system in nature, with transdermal drug delivery. A biologically inspired micropillar
patch was fabricated that is self-adhesive, reusable, and can sustain a controlled drug release. We
successfully preloaded the commercial non-steroidal anti-inﬂammatory generic drug unguents
indomethacin, ketoprofen, diclofenac sodium and etofenamate into a polydimethylsiloxane elastomeric
matrix and fabricated drug-containing micropillar patches. When examining the drug release kinetics and
friction of the patches, we observed that these drug unguents can be released calculably and regularly for
several days. Additionally, the drug unguents released from the patch to its attached surface are critical to
increase the strength of the patch's adhesion, which is based on capillary attractive forces and is inspired
by beetle feet. Here, we create a novel system combining biomimetics and drug delivery that can be
modiﬁed for use across the biomedical and engineering spectra. Motivation: the objective of the present
study was to characterize a micropillar PDMS patch that was inspired by a beetle's wet adhesion as a
platform for conducting in vitro release studies. Commercially available non-steroid anti-inﬂammatory
drugs (NSAIDs) were used as the model drugs for our delivery systems. An emphasis was put on
quantitatively evaluating the drug release and friction manifestation of these patches.1. Introduction
Transdermal drug delivery (TDD) is an attractive method,
oﬀering opportunities to address the low bioavailability of many
oral drugs and to avoid the pain and inconvenience of intrave-
nous (i.v.) drug administration.1 In practice, the advantages of
transdermal administration include high patient compatibility
with the treatment, the ability to discontinue the treatment at
any time, a controlled rate of drug delivery to the patient, a xed
plasma drug level and the elimination of the hepatic rst-pass
eﬀect.2 TDD systems currently include several types of trans-
dermal patches, and at least three generations of manufacture.3
However, all of these transdermal patches contain an adhesive
layer, need rm contact with the skin, and ensure that the drugs
access the systemic circulation at a controlled release rate. Here,
we propose that in cases of a self-adhesive patch matrix, a
special adhesive layer is not needed. Hence, a bandage inspired
by insects' feet is a possible matrix upon which to construct an
auto-adhesion TDD composite (Chart 1).
The adhesion that occurs on the feet of some insects and
animals has been attributed to a combination of molecular
interactions and secretion-mediated capillary attractive forces.4g, National Chung Hsing University, 250
ROC. E-mail: ccchang555@dragon.nchu.
tion (ESI) available. See DOI:
Chemistry 2013Because some insects produce secretory uids in the contact
area5 but others do not (spiders and geckos),6 sciec3tb20735h-
ttists can expect that diﬀerent basic physical forces contribute
to the overall adhesion. Aer studying these adhesive systems,
many scientists have mimicked water beetle feet,7 tree frog
toes,8 and gecko toes9 when engineering materials for techno-
logical applications. The advances in understanding such
mechanisms are relatively recent. We are most interested in theChart 1
J. Mater. Chem. B, 2013, 1, 5963–5970 | 5963
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View Article Onlinedevelopment of wet adhesion for medical purposes, including
recent research showing that an endoscopic video capsule can
stop and anchor itself within the internal intestinal surface due
to an enhanced adhesive and frictional micropillar array.10
Additionally, a treatment tape for surgical and traumatic
wounds was designed with nanoscale pillar arrays, which can
enhance the properties of an internal tissue.11 It seems that wet
adhesion has a broader biomedical engineering utility than dry
adhesion. Recently, dry adhesion nano- or micro-ber arrays
were coated with adhesive proteins secreted by marine animals
to construct friction enhancing wet elastomeric adhesive
tapes.10,12 Consequently, a bandage inspired by gecko feet was
constructed and suggested as an eventual replacement to
suturing.13 However, there has been no discussion of their use
in TDD until now. In this manuscript, we study the eﬀects on
the adhesion force of a wet adhesion system when preloading a
drug into the elastomeric matrix. The goal of this study is to
improve the design of micromanipulation systems by incorpo-
rating capillary forces, an idea learned from bio-mimicking.
Because elastomers are commercial polymers that oﬀer
unique biocompatibility characteristics and are not biodegrad-
able, they are widely used in biomaterials,14 particularly in
medical devices for drug delivery15 or drug release.16 Among
medical grade silicones, PDMS (polydimethylsiloxane) and
PDMS-based elastomers not only satisfy the above standards but
can also be used in skin topical applications and long term
implants.17 The literature indicates that PDMS can release low
molecular weight siloxane (an oil),18 a homogeneous lubricious
alcohol,19 or lignocaine.20 Furthermore, PDMS/silicone resin
networks,matricesmadeof siliconepressure-sensitiveadhesives,
are used in numerous TDD systems to aﬃx the drug device to the
skin.21More importantly, PDMShasbeen successful as a reusable
micro-scale mold to fabricate microneedles.22 Most of the adhe-
sion systems described above that were made of nano- or micro-
ber arrays were constructed from PDMS or PDMS-based
elastomers. Overall, the properties of PDMS are suitable for the
fabrication of nano- or micro-arrays, as well as for the formation
of a drug-releasing matrix. Thus, we chose PDMS as the matrix
material to fabricate our bio-inspired self-adhesive TDD tape.Fig. 1 A ﬂow chart showing the preparation of the drug-containing micropillar p
5964 | J. Mater. Chem. B, 2013, 1, 5963–59702. Experimental
2.1 Materials
2.1.1 Silicone matrix. Polydimethylsiloxane (PDMS, Dow
Corning Inc., Midland, MI, USA), a so elastomer, was selected
as the material used in the micro-pattern because PDMS can be
easily fabricated and is biocompatible.23 It is a room-tempera-
ture vulcanizable (RTV) silicone consisting of two liquids, A and
B, which are packaged separately. The rst liquid contains the
monomer and the inhibitor, and the second contains the
crosslinking promoting agent (platinum salt).24 Here, we
prepared three raw elastomers made of three types of silicone
grade PDMS, Silastic T-4, Sylgard 184, and Dow Corning
SE1740. The patches were fabricated under diﬀerent prepara-
tion conditions.25
2.1.2 Preparation of micropillar patches. As seen in Fig. 1,
the two components of the silicone aremixed together (at a ratio
of 10/1 monomer/catalyst, w/w) in ultrasonic baths to obtain a
homogeneous, low viscosity liquid. The PDMS mixture is then
poured over a mold of micro-holes with a dened geometry
(hole diameter ¼ 2 mm, height ¼ 2 mm and period ¼ 4 mm),
degassed (10 mmHg) in a vacuum chamber for 20 min, and
cured without heating. We prepared the patches containing the
drug (or oil) using the same procedure, by mixing the drugs with
the A and B liquids (each patch included 1 g or 1 O.D. of drug).
Finally, the PDMS patch was peeled away from the mold used to
fabricate micropillars. A representative sample of the resulting
molded micropillars is also shown in Fig. 2. The transparent
elastomeric tape was identied by lighting it with a laser point;
as shown in Fig. 2(a), the regular pattern of laser-induced bright
spots that mimicked the micropillar spacing of the tape was
evident once the curing and casting processes were successful.
A scanning electron microscopy micrograph was used to check
the structure and regularity of the pillars on the patch, as shown
in Fig. 2(b) and (c).
Consider the mechanical stability and surface energy of the
micropillar patch. Long bers tend to be mechanically unstable
and may collapse as a consequence of their own weight or
cluster if the adhesive forces between the contact tips becomeatches.
This journal is ª The Royal Society of Chemistry 2013
Fig. 2 (a) Identiﬁcation of the PDMS micropillar array using a laser point. (b) A
scanning electron microscopy micrograph of the patch shown in (a), with an
approximate diameter of 2 mm, an approximate height of 2 mm and a pillar
spacing of 4 mm (center to center). (c) The same array as that shown in (b), but at a
45 angle view.
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View Article Onlinestronger than the forces required for bending.26 That is,
bending or condensation easily occurs around pillars with a too
small radius or around those that are too long or too close.
Hence, an adhesive structure consisting of micro- or nano-bers
with radii, lengths and inter-ber distances (density) should
follow the criteria of “adhesion design maps”, which are based
on the comprehensive evaluation of the ber fracture, ideal
contact strength, ber condensation and ber adaptability.27
Moreover, thinking about the wet adhesion system, whether
coating or preloading, the pillars will become heavy and the
inter-ber distance is shortened. Larger spacing and shorter
diameter are favourable to prevent the ber or pillar from
condensation. Following these considerations above, we design
our micropillar tape at this stage.
2.1.3 Therapeutic agent. Hydrocortisone and ()-nicotine
were obtained from Acros Organics Co. Thiamine hydrochloride
was purchased from Sigma, and methyl salicylate was obtained
from Alfa Aesar. The NSAIDs used included etofenamate, con-
taining Teiria gel (5%w/w, U-Chiu Pharmaceutical Co., Taiwan);
diclofenac sodium, containing Canfol gel (1% w/w, Fu-Yuan
Chemical & Pharmaceutical Co., Ltd, Taiwan); ketoprofen,
containing Fastum gel (2.5% w/w, A. Menarini, Italy); indo-
methacin, containing anodyne solution (1% g ml1, Root
Chemical Pharmacy Co. Ltd, Taiwan); methyl salicylate,
containing mentholatum deep heating rub (TTY Biopharm.
Co., Ltd, Taiwan); and dimethyl silicone oil (KF-96 1000 c.s.,
Shin-Etsu).
2.2 Measurements
2.2.1 Adhesion experiments. Adhesion experiments were
performed to determine the pull-oﬀ phenomena of removing
each strip of themicropillar tape from glass. Buckets containing
various weights of water were hung from a patch adhered to
glass. The friction results were described by either tensile force
testing (a bucket hung from a patch with its glass mounted on
the ceiling) or shear force testing (a bucket hung from a patch
with its glass mounted on the wall). To hang a bucket, poly-
urethane foam was aﬃxed to the back of a patch, as shown in
Fig. 1, and then a hook was gummed to the foam.
2.2.2 Controlled release of the drug. The fabricated sili-
cone patches were attached to a piece of smooth glass, which
was removed once a day (from days 1 to 8). The amount of the
drug released was determined by measuring the absorption
signal of the reagents remaining in the tapes. The absorption ofThis journal is ª The Royal Society of Chemistry 2013the tape was measured via UV spectroscopy (Thermo Genesys 6
UV-visible spectrophotometer). To create control curves for
comparison, the basic absorption and emission spectra of the
generic drug and ointment mixtures were collected and are
shown in Fig. S1.†3. Results and discussion
3.1 Fabrication of the PDMS micropillar patches
At rst, it is necessary to evaluate the mold-casting and drug-
releasing abilities of the fabricated micropillar patches. Aer
fabricating as described in the Experimental, the produced tape
made using Silastic T-4 was the hardest of the three tapes,
while that made using Dow Corning SE1740 was the stickiest
and the most elastic. These three silicone grade PDMS elasto-
mers were used in this work to determine the optimal balance
between the drug release rate and the friction of wet adhesion
tapes. In fact, an earlier report showed that dimethyl silicone oil
can be released from PDMS.18 Thus, in the rst stage we
incorporate dimethyl silicone oil into the PDMS elastomers
listed above before curing the patch, qualitatively observing the
oil release from the patch. In the meantime, in order to better
observe the drug releasing conditions, we quantitatively
measured the kinetic release of the oil by dissolving a trace of
uorophore powder in the silicone oil. Consequently, the uo-
rescence emission signal of the uorophore-inclusive uores-
cent oil was the criterion to numerically evaluate the controlled
drug release. Aer an initial screening, we found that all three
micropillar PDMS tapes could constantly release the silicone
oil, but only the tapes molded of Sylgard 184 and Dow Cor-
ning SE1740 PDMS released the uorophore (Fig. S2†). The
uorophore was retained in the matrix of the Silastic T-4 tape.
Thus, for a solute-solvent mixed drug system, Silastic T-4 tape
is not suitable to be a containing matrix because it only releases
the solvent, not the solute. Additionally, Dow Corning SE1740
PDMS tape is diﬃcult to peel from the mold, though it can
release a powdered uorophore without requiring a solvent like
silicone oil (data not shown). In summary, the micropillar tape
made from Sylgard 184 PDMS is the most suitable matrix to
contain a drug such as the ointment mixtures used in this paper
(described in the Materials section).3.2 The wet adhesion of micropillar patches containing
silicone oil
We are interested in not only the release of oil from the man-
ufactured tapes but also the change in the wet adhesion of the
micropillar tape containing oil. Adhesion experiments were
performed on Sylgard 184 micropillar tapes, both unloaded
(termed dry adhesion) and loaded with dimethyl silicone oil
(wet adhesion). The peel-oﬀ force was easily determined for
each tape by tensile force testing (in which the bucket hangs
downward when the glass is aﬃxed to the ceiling) and shear
force testing (in which the bucket hangs to the side of the patch
when the glass is aﬃxed on the wall, as shown in the insets of
Fig. 3). Various weights of water-containing bottles were used to
reach the failure point, and the mean force values are plotted inJ. Mater. Chem. B, 2013, 1, 5963–5970 | 5965
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View Article OnlineFig. 3 as a function of the loading percentage of oil. The
experimental results indicate that a certain ratio of silicone oil
can result in an increased frictional force. In the side hanging
case, the shear force reaches a maximum of 5 N cm2 when the
dose percentage of the silicone oil is 5%. A maximum tensile
force of 9.6 N cm2 is reached in the hanging case when 15% oil
is used. Both of these forces are larger than those obtained with
only the dry adhesive patches. However, the frictional forces
decrease when silicone oil preload percentages of above 5% or
15% are used in the hanging and side hanging micropillar
patches, respectively. We propose that an excess amount of oil
will ll the space between the pillars and destroy the van der
Waals interactions that normally aid adhesion. Furthermore, in
the side hanging case, the micropillar tape containing excess oil
is very easy to slide along the wall when lateral force is applied.
That slide is why the wet adhesion eﬃciency of the side hanging
tape is lower than that of the hanging tape. Nevertheless, the
wet adhesion micropillar tape that is inspired by beetles was
successfully fabricated to continually release a contained liquid.
Following the results and discussions above, a generic drug
dosage of 5% was selected to complete the following studies.
Based on the descriptions in the Introduction, there is no
doubt that the friction should dramatically increase once a at
patch (non-micropillar) becomes a micropillar structure.
However, the literature also mentioned that the viscosity of
coating oil may aﬀect the frictional force.10,12 That is, we should
take the viscosity eﬀect of preloading oil into consideration.
In our system, the friction of the dry at patch is lower than
0.3 N cm2. Furthermore, the oil-preloaded at patch never
achieved twice the value of friction force, as shown in Fig. S3.†
Hence, relative to the at patch, we infer that contributions to
the frictional force of the micropillar patch are predominantly
from the micropillar structure, and this kind of adhesion may
further increase with appropriate oil doping which is due to the
capillary attractive force but not to the viscosity of the secretion
(the oil released from the tape).Fig. 3 The results of a friction test on the Sylgard 184 micropillar patch with
variable weight percentages of preloaded silicone oil. The tensile force test of a
hanging bucket, suspended from a patch aﬃxed to the ceiling, is shown in blue.
The shear force test of a side hanging bucket, suspended from a patch aﬃxed to
the wall, is shown in red.
5966 | J. Mater. Chem. B, 2013, 1, 5963–59703.3 Release kinetics of the drug-containing micropillar
patches
We wanted to evaluate whether the inclusion of reagents would
interfere with the polymerization of PDMS during the micro-
pillar patch preparation. The experimental procedures were
performed as described above; generic drugs were mixed with
ointments from the drugstore, and the mixture was preloaded
into the PDMS solution before the silicone was cured. The
preloaded drugs hydrocortisone, etofenamate, diclofenac
sodium, ketoprofen, indomethacin and methyl salicylate were
molded successfully into the PDMS micropillar patches, as
expected. However, we found that the addition of nicotine or
thiamine hydrochloride hindered PDMS polymerization, pre-
venting the production of a exible transparent patch. Fig. 4
illustrates the release kinetics of the generic drugs that were
successfully incorporated into the Sylgard 184 silicone
elastomer.
As described above, in order to quantitatively determine the
amount of drug released from the patch, we measured the
intensity of the absorption signal of the drug which remained
in the tape. The results show that preloaded etofenamate and
diclofenac can easily be released from the PDMS patches. Aer
4 days of adhesion (with a new piece of glass aﬃxed everyday),
approximately 55% of the active ingredient was released. The
ketoprofen-containing patch had a lower release percentage
(20%), likely due to the more viscid property of the ingredient,
causing larger deviation from the curve norms. Spectral
detection showed that hydrocortisone and indomethacin are
only marginally released from the gel, even when the moni-
toring period is extended to 8 days (data not shown), indi-
cating that these drugs were contained within the patches. A
signicant amount of methyl salicylate was released from its
patch in the very early stages; we clearly observed the
absorption signal of methyl salicylate once the drug-containing
patch had been cured, but the signal was completely reduced
over the course of mere hours. We inferred that this initial
burst eﬀect occurred because the methyl salicylate was
deposited only on the surface of the patch and was not phys-
ically incorporated into the silicone matrix. A similar
phenomenon was also found in a silicone polymer matrix
containing lidocaine hydrochloride in another study.28 On the
other hand, the release eﬃciencies between micropillar and
at patches were also checked. Based on the result from Fig. 4,
the etofenamate and diclofenac preloading PDMS patches
have better drug release curves than others. As observed from
the at patches under similar experimental conditions,
Fig. S4† showed that only 17 and 20.5% of etofenamate and
diclofenac were released aer 4 days of adhesion, respectively.
It is reasonable to conclude that the micropillar structure can
provide a larger surface area for drug release, with respect to
the at structure.
In order to enhance the releasing eﬃciency without chemi-
cally modifying the PDMS structure, the addition of penetration
enhancers is a common choice which should be non-immu-
nogenic and rapidly reversible, to increase transdermal drug
delivery into and through the skin.29 There are some successfulThis journal is ª The Royal Society of Chemistry 2013
Fig. 4 The time dependent release percentages of the generic drugs hydro-
cortisone, etofenamate, diclofenac sodium, ketoprofen and indomethacin that
were preloaded into PDMS micropillar patches. The dimethyl silicone oil doping
results for the indomethacin and ketoprofen systems are also shown. A patch was
attached to a glass surface, which was changed once a day. The inset shows the
spectra of the etofenamate remaining in the patch over the course of the
experiment.
Fig. 5 A diagram of the relationship between the lipophilicity log P of a
drug and its kinetic release (the slopes of the ﬁtting curves from (b)). The
dimethyl silicone oil doping results for the indomethacin and ketoprofen systems
are also shown.
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View Article Onlineexamples of modiers that increase the amount of drug
released, such as polymer carriers28 and excipients.30 Although
the release of the drug may be optimized, the enhancers may
also aﬀect the properties of the drug or patch. Thus, in order to
improve the results shown in Fig. 4, we attempted to use
dimethyl silicone oil as a carrier for hydrocortisone, indo-
methacin and ketoprofen. Based on the results from Fig. 4, the
generic drugs with the lowest delivery rates were dissolved in
silicone oil (5% total weight) before being added to the PDMS
mixture. It is clear that the release slopes of the indomethacin
and ketoprofen systems increased over the 4 days of the
experiment, with release amounts increasing from 6 to
approximately 40% and from 21 to approximately 38%,
respectively. The hydrocortisone system underwent the same
addition of silicone oil, but no improved release was seen.
Regardless of the method used to incorporate the drug, the
hydrocortisone-releasing curve remained unchanged over both
short and long periods.
Fig. 4 also shows that the release kinetics of all the samples
were calculable and uniform. Their spectral patterns were
unchanged aer 4 days, meaning that these drugs were stable in
the PDMS matrix over a long period. Indeed, a plateau in the
spectra was observed for all of the samples. Although the
plateau eﬀect is relative to the patch thickness, it is actually
attributed to the hydrophobicity of the silicone matrix, which
traps the drugs and prevents them from disseminating into theThis journal is ª The Royal Society of Chemistry 2013buﬀer solution. As illustrated in Fig. 5, a diagram of the kinetic
release (the slopes of the tting curves from Fig. 4) versus the
lipophilicity log P clearly shows a linear relationship. Similar
results were also observed in a diagram of the relationship
between the lipophilicity log P and the amount of total drug
released from the patches. This result indicates that the PDMS
matrix is suitable for delivery of more lipophilic dugs, especially
etofenamate and diclofenac. Furthermore, because hydrocorti-
sone and methyl salicylate were not suitable for a Sylgard 184
PDMS matrix, and nicotine and thiamine hydrochloride dis-
rupted the polymerization of the PDMS elastomer, we
concluded that NSAIDs would be suitable drugs for a multi-day
release from a beetle-inspired micropillar PDMS medical
device.
As an additional consideration, we found that pure chem-
icals ketoprofen, indomethacin and diclofenac sodium were
solid powders at room temperature, while etofenamate was
liquid. On the other hand, in the generic drug ingredients
(containing a drug solute and a solvent or polymer carrier) we
investigated in this study, the solvent could be alcohol, silicone
oil, Vaseline (petrolatum-based) or even some L-menthols. In
most cases, these solvents were mixed with each other and used
to manufacture formulations. Hence, in our system, it is very
possible that the solvents of ingredients evaporated during the
curing procedure, which may reduce the eﬃciency of drug
releasing from the patch. To conclude the lipophilicity, solvent
evaporation and physical state of the compound, these factors
by themselves may be the reasons for diﬀerent releasing eﬃ-
ciencies between these NSAIDs and the possible reasons why
the etofenamate and diclofenac can release from patches well
without adding a solubilizing agent (dimethyl silicon oil).
Nevertheless, from our results, the important message is that a
commercial generic NSAID drug mixture can be successfully
doped into a PDMS matrix to construct a biomimetic TDD
system.J. Mater. Chem. B, 2013, 1, 5963–5970 | 5967
Fig. 6 The time dependent friction tests of the dimethyl silicone oil and the
generic drugs (etofenamate, diclofenac, ketoprofen and indomethacin) that were
preloaded into the PDMS micropillar patches. These wet adhesion experiments
are compared with the control unloaded micropillar patch (dry adhesion). (a)
The tensile force test, using a hanging bucket. (b) The shear force test, using a
side hanging bucket. The patch was attached to a glass surface that was changed
once per day.
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View Article Online3.4 Wet adhesion or friction of the drug-containing
micropillar patches
Adhesion experiments similar to those described in Fig. 3 were
performed for wet adhesion PDMS micropillar patches that
were preloaded with a drug. If the drug released from the TDD
system can be made to mimic the secretions seen in the feet of
insects and animals, wet adhesion, which can be attributed to
capillary attractive forces, will be stronger than dry adhesion. As
expected, the experimental results shown in Fig. 6 indicate that
the inclusion of a 5% dose of commercial generic NSAIDs
resulted in an increased adhesion force, whether the measure-
ment was tensile or shear. However, we also observed that the
adhesive strengths of all the patches decreased with time. The
decay of the control patch's dry adhesive ability is likely due to a
degradation of the pillar structures on the polymer surface with
repeated use. This phenomenon also occurred in the patches
preloaded with a drug and was particularly serious in the shear
force measurement.
Furthermore, the more drug that is released from a patch,
the more closely the experimental patch resembles the dry
adhesion control due to a lessening of the capillary attractive
forces. Additionally, it is possible that the released drug will also
ll the space between the pillars where the patch is not in
contact with the glass. As a result, the excess amount of oil or
liquid drug could destroy the van der Waals interactions, as
described in Fig. 3. As can be seen in Fig. 6, the better drug
releasing patches, such as the etofenamate and diclofenac
systems, show the adhesion decays more quickly than the other
systems. On the other hand, as mentioned above, ketoprofen is
the stickiest of these drug ingredients. Thus, the ketoprofen
system is the most adhesive patch and it maintains its adhesion
with less apparent decay. Nevertheless, these wet adhesion
results illustrate that the preloaded patches have higher adhe-
sion strengths than do the unloaded PDMS patches in both
tensile and shear adhesions, even though their adhesions decay
with multiple uses.3.5 Predicting the skin application
The optimal drugs found in this study for inclusion into our
designed PDMS matrix, to be released over a period of several
days, were etofenamate and diclofenac. Indeed, this device
could promote the release of these therapeutic molecules when
the device is attached to the skin, which can absorb a drug stage
by stage. Once we determined that our system could be used as
a TDD system, we attached the NSAID-containing micropillar
patches to oil-blotting paper (a special oil absorbing paper oen
used on the face), instead of glass, to mimic the eﬀects of the
TDD on the skin and reevaluate its release kinetics. As shown in
Fig. 7, approximately 52% (a 12% increase), 48% (a 10%
increase), 68% (a 13% increase) and 65% (a 15% increase) of the
total contained drug was released from the indomethacin,
ketoprofen, diclofenac and etofenamate systems, respectively.
Both the amounts and release rates of the NSAIDs delivered in
this method were apparently increased as shown in Fig. 3. Here,
we also observed the plateaus in the curves, which occurred
early; the increasing release rates for these drugs were identical5968 | J. Mater. Chem. B, 2013, 1, 5963–5970to those previously described. Therefore, we conclude that this
phenomenon is caused by the drug concentration gradient,
which is more pronounced between the oil-blotting paper and
the patch than it was with the glass.
It is known that the oral NSAIDs can inhibit cyclooxygenase
isoenzymes (COX-1 and COX-2) and result in reduced synthesis
of prostaglandins,31 provide analgesia and relief from inam-
mation, are used to reduce the concentration of prostaglandins
at the site of injury resulting in decreased pain and inamma-
tion.32 However, NSAIDs can also lead to an increased risk of
gastrointestinal33 and cardiovascular adverse events.34 The
superiorities of TDD, as described in the Introduction section,
can avoid the side eﬀects of NSAIDs. TDD administered NSAIDs
penetrate slowly and in small quantities into the systemic
circulation. These approaches also prevent high local drug
levels in the alimentary tract and direct toxicity of NSAIDs with
reduction in the total daily dosage of systems, especially in long
term treatment.35 Finally, TDD applied NSAIDs have a superior
safety prole to oral formulations.
Here, in our system, the results in Fig. 4 and 7 indicate that
the absorption capability of a substance (e.g., skin) can aﬀectThis journal is ª The Royal Society of Chemistry 2013
Fig. 7 The time dependent release percentages of the generic drugs etofena-
mate and diclofenac sodium, as well as oil-doped ketoprofen and indomethacin,
which were preloaded into PDMS micropillar patches. The patches were attached
to a surface of oil-blotting paper, which was changed once per day.
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View Article Onlinethe drug release of our patch. That is, the properties of the
substance to which the patch is attached may inuence the
quantity and rate of drug release. Thus, in our micropillar wet-
adhesion patches, we not only retained the superiorities of TDD
but also promoted the applications of TDD. Once these solvents
or polymer drug carriers are incorporated into a TDD system,
they will be suitable wet-adhesion patches, constructed based
on the idea of capillary attractive forces that are mediated by
secretions. In our study, the commercial ingredients etofena-
mate, diclofenac, ketoprofen and indomethacin were successful
examples. This issue can be commercialized immediately with
low-cost unguents (commodities) and simple manufacture
procedures, especially in etofenamate and diclofenac cases.
Moreover, these successful drug-containing micropillar patches
can be removed and reused several times.
4. Conclusions
In this manuscript, we constructed a new drug delivery
method that combined biologically inspired wet adhesion with
transdermal drug delivery. PDMS, oen used as the matrix of a
TDD system, was easily molded to become a micropillar patch.
Here, we successfully preloaded commercial generic NSAIDs
into the Sylgard 184 PDMS elastomer and made the silicone
into drug-containing TDD micropillar patches. The dis-
tinguishing features of the manufactured patches are
described below. (1) The drug is released from the patch in a
controlled manner that is both quantitative and uniform. (2)
The adhesion strength is increased due to the drug unguents
released from the patch, based on the designed capillary
attractive forces that were inspired by beetle feet. (3) The patch
is self-adhesive and can be removed and reused several times.
(4) All of the raw materials used are biocompatible, cheap
and safe. We believe that this platform can be broadened to
other generic drugs once the polymer matrix is modied
appropriately.This journal is ª The Royal Society of Chemistry 2013Acknowledgements
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